Stock EMBT EMBER THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Ember Therapeutics, Inc.

Equities

EMBT

US29082W1099

Market Closed - OTC Markets
Other stock markets
 07:32:31 20/09/2023 pm IST 		5-day change 1st Jan Change
0.0001 USD -.--% Intraday chart for Ember Therapeutics, Inc. -.--% -.--%
2019 Viscogliosi Brothers LLC cancelled the acquisition of OP-1 Portfolio Program from Ember Therapeutics, Inc.. CI
2018 Viscogliosi Brothers LLC entered into a letter of intent to acquire OP-1 Portfolio Program from Ember Therapeutics, Inc.. CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alternative Liquidity Index LP Announces an Extension of the Tender Offer for Ember Therapeutics, Inc.
AQ
Viscogliosi Brothers LLC cancelled the acquisition of OP-1 Portfolio Program from Ember Therapeutics, Inc..
CI
Viscogliosi Brothers LLC entered into a letter of intent to acquire OP-1 Portfolio Program from Ember Therapeutics, Inc..
CI
Ember Therapeutics, Inc. acquired the assets of of Dermasilk Brands, Inc. from Midwood Distributors, Inc. for $1.3 million.
CI
Knight Therapeutics Inc. and Ember Therapeutics, Inc. Expand Distribution Partnership
CI
Ember Therapeutics, Inc. entered into a definitive agreement to acquire the assets of Migralex, Inc. for $0.87 million.
CI
Ember Therapeutics, Inc. acquired ICX-RHY/Vavelta from Intercytex Limited for $1.1 million.
CI
American Home Alliance Corp will Change its Ticker to EMBT from AHLL
CI
AMERICAN HOME ALLIANCE CORP will Change its Name to Ember Therapeutics, Inc
CI
Ember Therapeutics, Inc. acquired American Home Alliance Corp. in a reverse merger transaction.
CI
Ember Therapeutics, Inc. Announces Initial Positive Results from a Phase 2 Trial of BMP-7
CI
Mariel Therapeutics, Inc. acquired Ember Therapeutics, Inc. from Third Rock Ventures II, L.P. of Third Rock Ventures II, L.P. and others for $6 million.
CI
Ember Therapeutics, Inc. acquired Worldwide License of BMP-7 and OP-1 Portfolio from Stryker Corporation.
CI
Ember Therapeutics, Inc. Announces Publication of Key Preclinical Data Demonstrating Inhibition of Transient Receptor Potential Vanilloid
CI
Ember Therapeutics, Inc. Announces Management Appointments
CI
Ember Therapeutics, Inc. Closes License Deal with Joslin Diabetes Center
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EMBT Stock
  4. News Ember Therapeutics, Inc.